Addition of Metformin to Liraglutide, A GLP-1 Receptor Agonist, Improves Glycemic Control in Patients with Type 2 Diabetes Mellitus
Journal Title: Journal of Diabetes and Obesity - Year 2016, Vol 4, Issue 1
Abstract
Background: The maximum permissible dose of liraglutide, a GLP-1 receptor agonist, under the Japanese Heath Insurance system is 0.9 mg/day. We determined the effects of adding metformin to liraglutide therapy in Japanese patients with type 2 diabetes. Material and Methods: This observational retrospective study included 47 patients with type 2 diabetes who were treated with liraglutide alone or in combination with sulfonylureas. Metformin was added at a dose ranging from 250 to 500 mg/day based on inadequate glycemic control. Liraglutide and metformin doses were converted from mg/day to mg/kg body weight/day before analysis of the correlation between the dose and changes in glycated hemoglobin (HbA1c) and body mass index (BMI). Results: Both HbA1c and BMI decreased significantly after 24 weeks of the combination treatment. Mild gastrointestinal adverse events were reported by 21% of the patients. Only the dose of metformin, but not that of liraglutide, expressed in mg/kg body weight was correlated significantly with decrease in HbA1c and BMI. Conclusions: The addition of metformin to the maximum permissible dose of liraglutide helps secure glycemic control and reduce BMI in Japanese patients with type 2 diabetes who exhibit inadequate response to liraglutide.
Authors and Affiliations
Masao Toyoda
Keywords
Related Articles
- EP ID EP417851
- DOI 10.15436/2376-0494.17.1300
- Views 76
- Downloads 0
Addition of Metformin to Liraglutide, A GLP-1 Receptor Agonist, Improves Glycemic Control in Patients with Type 2 Diabetes Mellitus
Background: The maximum permissible dose of liraglutide, a GLP-1 receptor agonist, under the Japanese Heath Insurance system is 0.9 mg/day. We determined the effects of adding metformin to liraglutide therapy in Japanese...
Estimated Stearoyl-CoA-desaturase (SCD)-1 and Elongase of Very Long Chain Fatty Acids (Elovl) 6 Activities From Serum Fatty Acids Are Reciprocally Associated with Visceral Fat Area in Type 2 Diabetic Patients
Introduction Abdominal visceral fat accumulation can cause insulin resistance in type 2 diabetic patients We investigated the association between serum fatty acid levels and the visceral fat area VFA Materials and...
Effect of Chromium(III) -Amino acid (1:3)Complexes on High Sucrose Induced Insulin Resistance, Lipid Abnormalities - Oxidative Stress in Male Sprague Dawley Rats
This study was carried out to assess the anti-hyperglycaemic effects if any of novel synthetic binary chromium (III)-amino acid complexes in a high sucrose (HS) induced insulin resistance (IR) and or impaired glucose tol...
Prophylactic Effect of Dietary Supplementation of Fish Oil Extracted from Sardinella Longiceps on Renal Dysfunction in Alloxan Induced Diabetic Mice (Mus Musculus)
emsp emsp Diabetes mellitus is a multifactorial metabolic disorder caused due to deficiency of pancreatic hormone insulin which results in failure to metabolize sugar or due to adequacy of another pancreatic hormone...
Composition Diversity and Abundance of Gut Microbiome in Prediabetes and Type 2 Diabetes
Association between type 2 diabetes (T2DM) and compositional changes in the gut micro biota is established, however little is known about the dysbiosis in early stages of Prediabetes (preDM). The purpose of this investig...